Driver Gene Mutations Reprogram Lipid Metabolism in Non-Small Cell Lung Cancer.
- 1Department of Thoracic Surgery, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, China.
Abstract
Non-small cell lung cancer (NSCLC) is among the leading causes of cancer-related deaths worldwide. Previous treatment regimens often have limited efficacy due to drug resistance and recurrence. Metabolic reprogramming participates in the initiation and progression of NSCLC, with prominent changes in lipid metabolism. Mutations in specific driver genes directly remodel lipid metabolic reprogramming in NSCLC by rewiring lipid synthesis, uptake, and catabolism, which confers cancer cells with enhanced proliferative and metastatic capacity. On this basis, targeted lipid metabolism reprogramming has become a promising new direction for the treatment of NSCLC. In this review, we examined the alterations in lipid metabolism in NSCLC, explored the mechanisms by which driver gene mutations change lipid metabolism in NSCLC, and provided possible therapeutic strategies targeting key lipid metabolism pathways at the current stage, aiming to offer a theoretical basis and prospects for the development of novel therapies targeting specific gene mutation subtypes of NSCLC.
Related
- Lipid droplet-associated proteins integrate lipid metabolism, cell cycle, and cytoskeletal remodeling in colon cancer
- Lipid metabolism mediating oxaliplatin resistance in colorectal cancer
- Lipid Metabolism and Ferroptosis in Cancer: Regulatory Mechanisms, Alternative Splicing, and Therapeutic Implications
- Lipid metabolism: a potential checkpoint for cGAS-STING regulation in colorectal cancer
- Adaptation of breast cancer cells to serum-free defined medium reveals changes in proliferation, adhesion, and lipid metabolism
BibTeX
@article{lin2026driver,
title = {{Driver Gene Mutations Reprogram Lipid Metabolism in Non-Small Cell Lung Cancer.}},
author = {Jinxing Lin and Zhonghao Pang and Zhihua Jiang and Feng Li},
journal = {Cancer medicine},
year = {2026},
month = oct,
doi = {10.1002/cam4.72334},
url = {https://europepmc.org/article/MED/42910561},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Driver Gene Mutations Reprogram Lipid Metabolism in Non-Small Cell Lung Cancer.
AU - Jinxing Lin
AU - Zhonghao Pang
AU - Zhihua Jiang
AU - Feng Li
PY - 2026
DA - 2026/10/01
JO - Cancer medicine
DO - 10.1002/cam4.72334
UR - https://europepmc.org/article/MED/42910561
AB - Non-small cell lung cancer (NSCLC) is among the leading causes of cancer-related deaths worldwide. Previous treatment regimens often have limited efficacy due to drug resistance and recurrence. Metabolic reprogramming participates in the initiation and progression of NSCLC, with prominent changes in lipid metabolism. Mutations in specific driver genes directly remodel lipid metabolic reprogramming in NSCLC by rewiring lipid synthesis, uptake, and catabolism, which confers cancer cells with enhanced proliferative and metastatic capacity. On this basis, targeted lipid metabolism reprogramming has become a promising new direction for the treatment of NSCLC. In this review, we examined the alterations in lipid metabolism in NSCLC, explored the mechanisms by which driver gene mutations change lipid metabolism in NSCLC, and provided possible therapeutic strategies targeting key lipid metabolism pathways at the current stage, aiming to offer a theoretical basis and prospects for the development of novel therapies targeting specific gene mutation subtypes of NSCLC.
SN - 2045-7634
ER -